ALNY
$312.17+1.07 (+0.34%)
Alnylam Pharmaceuticals, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO...
Recent News
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, “Fool me once, shame on you; fool me twice, shame on me.” Well, the buy-the-dip crowd continued to get a masterclass in just that lesson on Friday. Once again, the stock market opened higher, and ... Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal
In early March 2026, Tenaya Therapeutics reported a reduced full-year net loss of US$90.6 million and highlighted encouraging preclinical and Phase 1 data for its HDAC6 inhibitor TN-301 in Duchenne muscular dystrophy and cardiomyopathy, alongside a new research collaboration with Alnylam Pharmaceuticals in cardiovascular genetics. The comparison of TN-301 against the approved pan-HDAC inhibitor givinostat, showing stronger preclinical muscle and cardiac effects without similar side-effect...
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya Therapeutics focused on RNAi based therapeutics for cardiovascular diseases. The agreement covers up to 15 novel genetic targets and includes milestone payment structures that indicate material relevance for Alnylam's business development plans. For context, Alnylam is known for its RNA interference platform, with a focus on genetic and rare diseases. Cardiovascular disease is a large and...